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Purpose: The emergency treatment of seizures is an important practical issue, in
particular the therapy of status epilepticus. Antiepileptic drugs for this condition
should be easy to use, show rapid action, have a long-lasting antiepileptic effect, and
have minimal cardiopulmonary and other side-effects. Unfortunately, none of the
presently available medications such as phenytoin and barbiturates seems to have al
of these four properties. Intravenous valproate became available some years ago and
first experiences show promising safety data and efficacy results.
Methods: We report a series of 102 adult patients who received standardized high
dosage intravenous valproate in various emergency situations, including status
epilepticus. The therapeutic goal was persistent seizure control, defined as successfu
interruption of clinical seizure activity within less than 15 min, followed by seizure
freedom during intravenous therapy for at least 12 h. All side effects were docu-
mented.
Results: In 83/97 patients (85.6%) the therapeutic goal was achieved. Serious side
effects were not documented in any patient. In particular there was no evidence of
sedation, cardiorespiratory disturbances and hypotension as often seen in barbitu-
rates and phenytoin. Mild side effects occurred in seven cases (6.9%).
Conclusions: The intravenous application of VPA seems to be an easy-to-use, safe and
efficient formulation as an alternative to phenytoin in all seizure emergency situa-
tions including status epilepticus. Further controlled comparison studies have to be
performed in the future.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.ress: Neurologische Univer-
m, Germany. Tel.: +49 621
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Valproate (VPA) is a well established first-line anti-
epileptic drug (AED) effective in a wide range of
focal and generalized seizures.1 There are several
conditions under which a parenteral preparation ofby Elsevier Ltd. All rights reserved.
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Table 1 Indications for intravenous valproate in 102
treatment episodes.
Treatment indication Patients
Status epilepticus 35
Simple-partial 12
Complex-partial 14
Generalized tonic—clonic 6
Absence 3
Series of seizures (two or more
seizures within 24 h)
34
Simple-partial 4
Complex-partial 2
Generalized tonic—clonic 27
Atonic seizures 1
Switch to intravenous therapy 25
Others 8
Total 102an AED is necessary, either because the patient is
unable to take oral medication or because a rapid
loading is required, e.g. in status epilepticus (SE).
Beside short-acting benzodiazepines, only pheny-
toin and phenobarbital are in wide use as an intra-
venous preparation. Unfortunately, these have a
narrow therapeutic window and a range of compli-
cating side effects significantly limiting their prac-
tical administration. Phenobarbital may lead to
major sedation and respiratory problems including
apnoea and is reported to increase the risk of infec-
tions. Phenytoin can cause cardiac arrhythmias,
requires an extra intravenous-line, has to be given
very slowly and may induce severe problems at the
injection site including the ‘‘purple glove syn-
drome’’.
Since the autumn of 1996, intravenous VPA is
available in Germany. The reported experiences
demonstrate a broad spectrum of indications ran-
ging from a rapid switch of oral to parenteral appli-
cation (e.g. children with severe gastroenteritis), to
series of seizures and life-threatening grand-mal SE
with promising safety data and efficacy results.1—6
Experimental data supported this clinical observa-
tions revealing both a fast and long-lasting antisei-
zure effect for VPA.7
Therefore, the goals of this retro- and prospec-
tive study were to test, (1) if intravenous VPA is a
safe and efficient treatment in heterogeneous con-
ditions of seizure activity including SE, and (2) if
these preliminary findings deliver promising results
for further controlled clinical trials.Methods
Patients
Data were available for 102 patients treated during
a 4-year period between December 1996 and
December 2000. Sixty-one patients (59.8%) were
male, 41 female (40.2%). The mean age was 54.8
years, range 18—85 years. The data of all patients
originated from a retrospective chart review. In 24
patients additional data from a prospective applica-
tion survey was available, 21 patients were super-
vised during treatment by the authors with regard to
this study.
Indication for rapid intravenous VPA treatment
ranged from (1) urgent need for or switch to intra-
venous VPA (n = 25), (2) series of seizures, (n = 34),
(3) status epilepticus in n = 35, to (4) others (n = 8)
such as brainstem seizures (n = 1), posthypoxic myo-
clonia (n = 2), and probably non-epileptic seizure
episodes (n = 5). These five patients were excluded
from the efficacy analysis. SE was operationallydefined according to the most recent classification
as ongoing seizure activity for more than 10 min.8
Series of seizures were defined as two or more
distinct seizures within 24 h with interseizure inter-
vals of regaining either consciousness or related
functions. For an exact overview see Table 1.
Procedures
All patients were either admitted as emergency
cases or were already hospitalized. Intravenous
VPA therapy was always applied under supervision
of an experienced epileptologist (BP or CP). Routine
clinical laboratory tests including electrolytes,
blood cell count, coagulation parameters, liver
enzymes and kidney function were conducted in
all patients, AED levels were measured in 97 of
102 patients. EEG (21-channel surface, Nihon Koh-
den Co.) was performed in all 35 SE patients and in
85 patients out of all 102 patients.
The patients received commercially available
intravenous VPA (Orfiril1 Injektionslo¨sung, Desitin,
Germany). The initial bolus application varied
between 4 and 16 mg/kg BW (body weight) depen-
dent on the severity of the clinical condition with
the majority (74%) of patients receiving 15 and
16 mg/kg BW, given within 5—10 min, followed by
a continuous infusion (flow control pump) of 0.5—
4 mg/kg BW/h maintenance dosage within 2 h to 10
days.
Precise data of individual dosage is given for all
35 patients being diagnosed with SE (Table 2).
Twenty-nine patients with SE or series of seizures
had been pretreated without success by standard
initial dosages for SE8 of benzodiazepines (11
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Table 2 Clinical data, dosage management and duration of intravenous valproate in 35 patients treated for status
epilepticus.
Case Age Sex Diagnosis Seizure type Bolus (mg) Infusion rate (mg/h) Duration
1 66 f Subdural haematoma SPS 500 — —
2 67 m Brain abscess SPS — 50 24 h
3 67 m Brain abscess SPS — 120 4 h
240 4 h
120 8 h
4 23 m Arteriitis nodosa GTCS 900 187.5 4 d
5 75 m Theophyllin—intoxication GTCS 900 62.5 2 d
600
6 58 m Cerebral venous thrombosis CPS 900 125 12 h
7 60 f Intracranial haemorrhage GTCS 900 50 24 h
8 18 m Epilepsy Absence 900 — —
9 62 f Epilepsy CPS 900 150 8 h
300
10 60 m Wernicke’s encephalopathy SPS 900 125 24 h
11 66 f Astrozytoma 8III SPS 600 37.5 2 d
12 68 f Epilepsy CPS 600 — —
13 68 f Epilepsy CPS 600 100 12 h
14 68 f Epilepsy CPS — 50 24 h
15 61 m Alcoholism, SVE CPS — 50 24 h
16 75 f Alzheimer’s disease CPS 900 125 12 h
17 39 m Brain injury GTCS 900 75 3 d
18 47 m Familial microangiopathy CPS 900 125 12 h
19 80 f Stroke GTCS 900 100 12 h
20 75 f Glioblastoma SPS 900 — —
900
21 75 f Glioblastoma SPS 900 — —
22 37 m Epilepsy Absence 900 83.3 24 h
23 46 f Multiple sclerosis CPS 900 125 12 h
24 54 m Epilepsy CPS — 125 12 h
25 74 m Cerebral metastasis SPS 600 62.5 24 h
26 63 m Intracranial haemorrhage SPS/GTCS 900 125 2 d
27 85 f Meningioma CPS 600 125 3 d
28 83 f Stroke GTCS/SPS 900 200 12 h
900 (90 min)
29 49 m Down-syndrome CPS — 62.5 24 h
30 83 f Stroke CPS 900 62.5 2 d
31 63 m Encephalopathy CPS 600 75 6 d
600 (1 h)
32 55 m Epilepsy GTCS 900 75 3 d
33 54 m Epilepsy Absence — 125 21 h
34 66 f Astrozytoma 8III SPS — 150 12 h
35 77 f Subcort. vasc. enceph. SPS 600 87.5 3 d
Second bolus directly after the first bolus, except where mentioned. SPS: simple partial seizure; CPS: complex partial seizure; GTCS:
generalized tonic—clonic seizure.patients clonazepam, 6 patients diazepam, 4
patients clonazepam and diazepam and 3 patients
midazolam), phenytoin (4 patients) or clonazepam
and phenytoin (1 patient), before receiving theVPA infusion. Sixty-seven patients had a known
history of seizures and were already treated with
other oral AED than VPA such as carbamazepine
and lamotrigine.
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Figure 1 Efficacy of intravenous valproate in 35 patients
with SE, in 34 patients with series of seizures, and in 25
patients who underwent switch from oral to intravenousAnalysis
We analyzed efficacy and side effects of intravenous
VPA. Primary outcome was defined as successful
interruption of clinical seizure activity within less
than 15 min, followed by seizure freedom during
intravenous therapy for at least 12 h in those
patients with SE. In those patients with series of
seizures or those undergoing medication changes,
the goal was seizure freedom during intravenous
therapy for at least 12 h. All patients were asked
if they experienced or had experienced any pro-
blems, which they thought were attributable to
their medication. All individual adverse events were
documented and analyzed.treatment (grey bars: seizure control and black bars:
treatment without success).Results
Tolerability and safety
Serious side effects were not documented in any
patient. In none of the 35 SE patients and in none of
the 34 patients with series of seizures were signifi-
cant cardiorespiratory side effects including hypo-
tension observed.
Mild side effects, reported by individuals being
conscious, occurred in 7 out of 102 applications
(6.8%): Three patients complained of an unspecific
feeling of warming with dizziness for some seconds
during fast bolus injection. One patient had to be
withdrawn because of a moderate generalized aller-
gic skin reaction, which disappeared within a few
hours after discontinuation of therapy. Another
patient had nausea and vomiting for 3 h which
stopped despite of continuation of the therapy
and one patient had mild fatigue. In one patient
we observed a transient tremor of both hands. There
were no reactions at the injection site.
Efficacy
Ninety-seven of the 102 patients were eligible for
efficacy analysis, as five patients had to be excluded
retrospectively because of the non-epileptic nature
of their seizures. In 83 of 97 patients (85.6%) the
primary outcome criterion of seizure freedom as
defined was achieved. Sub-group analysis showed
efficacy of intravenous VPA in 27 out of 35 patients
with SE (77.1%), in 29 out of 34 patients with series
of seizures (85.3%), and in all but one out of 25
patients who were switched to intravenous treat-
ment (96.0%), which is illustrated in Fig. 1. In the
last group of patients, two were seizure free, the
others had had seizures before the switch. Within
the SE group, patients with complex-partial SEresponded best (92.9% or 13/14 patients seizure
free), compared to simple-partial SE (83.3% or
10/12 seizure free), generalized tonic—clonic
(GTC) SE (66.7% or 4/6 patients) and atypical
absence-status (0/3).
Looking at the 14 cases with primary treatment
failure, the following three subgroups can be recog-
nized:1. Late responders: In five patients VPA was effi-
cient, but only after a delay. In three out of those
(two with a series of GTC, one with intravenous
VPA substitution) a GTC seizure recurred within
15 min: increased dosage of VPA finally led to
complete seizure freedom. In the remaining two
a simple-partial SE required the administration
of an additional bolus of 12 mg/kg BW VPA to
achieve complete seizure control.2. Highly drug resistant SE: Of these seven patients,
five were absolutely refractory to any AED treat-
ment: Two died still in SE due to their underlying
illness, two had an absolutely pharmacoresistant
SE (complex-partial and generalized tonic—clo-
nic, respectively) to any drug treatment lasting
for months and died later, one was discharged
while still having an intermittent atypical
absence-status and was lost to follow-up. Of
the other two patients, one had a complex-par-
tial SE due to a ganglioglioma and the other
simple-partial SE due to a brain abscess. Both
patients became seizure-free after surgical
treatment.3. Responders to other AEDs than VPA: Only two
patients were in this group. One patient had an
atypical absence-status, promptly reacting to
benzodiazepines, the other one had several
GTC seizures which got controlled by high dosage
of VPA, however, ending into a complex-partial
168 C.N.A. Peters, B. Pohlmann-EdenSE, which could be easily interrupted by a stan-
dard dosis of intravenous phenytoin.
Twenty-nine patients had received benzodiaze-
pines or intravenous phenytoin in standard adult
dosages8 without success before treatment with i-
ntravenous VPA. Five of these were refractory to
benzodiazepines and intravenous phenytoin in a
maximum dose and became seizure-free under in-
travenous VPA.Discussion
The emergency treatment of seizures is an impor-
tant practical issue. This is particularly true for SE,
where themortality rates may be still as high as 25%.
Early aggressive treatment seems to be absolutely
necessary in this life-threatening condition. The AED
should ideally fulfill the following criteria: (1) be
easy to use, (2) show rapid action, (3) have a long-
lasting antiepileptic effect, (4) finally, have minimal
cardiopulmonary and other side-effects. Unfortu-
nately, none of the presently available medications
such as phenytoin and barbiturates seems to have all
of these four properties.8
In our opinion, intravenous VPA might be an
interesting alternative in this context for several
reasons. It is well known to have a variety of action
sites in the experimental setting10 explaining its
excellent efficacy in most seizure types. In an elec-
trically induced SE-model in animals, VPA sup-
pressed seizure activity after 30 s,7 being faster
than diazepam and phenytoin, both of which showed
more prominent sedation.
The history of intravenous application of VPA in
patients is a fairly recent one. Since the first obser-
vations of its high efficacy combined with excellent
safety data in a small study group of patients with SE
by Price3, a few uncontrolled open studies fol-
lowed,4,5,2,6 all of them confirming the therapeutic
value of this new formulation.
Our own preliminary data have shown its good
antiepileptic effects both in a series of seizures and
in different kinds of SE including GTCS-SE, with a
success rate of approximately 80%. Interestingly,
intravenous VPA could terminate seizure activity
in most of the cases where different established
AEDs (benzodiazepines and intravenous phenytoin)
had previously failed. Our efficacy rates of up to 80%
and more correspond to other recent studies in
adults2—5 and children,6 where most patients had
also been pretreated unsuccessfully with standard
benzodiazepines. Treatment failure in our study
population mainly occurred in those individuals,
who were either refractory with any AED, had anunderlying life-threatening condition or revealed a
highly epileptogenic lesion such as a brain abscess.
Only two patients showed seizure control after a
switch to an alternative medication.
In the two small adult case series5,4 (n = 20 and
23, respectively), a treatment regimen with an
initial bolus treatment of 15 mg/kg BW and a sub-
sequent infusion with 1 mg/kg BW/h of either 5—
6 h5 or 24 h,4 interrupted on-going SE in 80—85% of
cases controlled by EEG-monitoring in one study.4
Major systemic side effects were not observed in
either study. Ueberall et al.6 treated 41 children in
SE, who had been refractory to benzodiazepines,
phenytoin and barbiturates before, by means of
intravenous VPA, using an initial bolus of 20—
40 mg/kg BW, followed by an infusion with 5 mg/
kg BW/h. SE could be successfully interrupted in 78%
(32 out of 41) of the children, in the majority
(n = 27) within 2—6 min. Seizure control was
assessed by EEG-monitoring in all patients.
There were no major safety problems in our
entire study group of 102 patients with a wide
spectrum of therapeutic indications. This is in per-
fect agreement with all above mentioned efficacy
studies, even in studies where very high dosages of
up to 9.6 g/d were applied,3 and with those studies,
in which the safety aspect of intravenous VPA was
particularly addressed.9,10 Due to the mainly retro-
spective character of our study, we might have
missed some minor side effects, which may not have
been documented in the charts but there have
clearly been no serious adverse events.
More recent experiences with high bolus applica-
tion of intravenous VPA with up to 40 mg/kg BW
and rapid loading with a rate of up to 6 mg/kg BW/
min11—14 demonstrate both excellent efficacy and
safety. The two manufacturers in Germany now
recommend an initial loading dose of 15 mg/kg BW
over a time period of up to 30 min followed by an
infusion at 1—2 mg/kg BW/h over 12—24 h, which is
close to the regimenwe used in our study. Meanwhile
we have administered dosages of 4800 mg up to
9600 mg over 24 h in cases of SE that were difficult
to treat, without any evidence of severe side effects.
The above reported high efficacy rates of >80%
including our own experience are very promising, but
have to be interpreted with caution, as they are still
results from open study designs, or retrospective
small case series.15 It is also difficult to compare them
with other data, as most publications with regard to
anyantiepileptic treatmentinSEareeitheranecdotal
case reports or open studies with only a small number
of patients. Systematic prospective comparisons of
different AEDs, randomized and double-blind, are
extremely rare: toourknowledgethereareonly three
studies,16—18 and only onewith a larger population.18
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comparison study, 570 patients randomly received
different therapeutic regimens (phenytoin, diaze-
pam + phenytoin, phenobarbital and finally loraze-
pam), but unfortunately VPA was not included. The
reported low efficacy rate of only 55% in this study,
independent of the chosen drug, is mainly due to
the selection of patients in this study and the long
duration of the SE before recruitment.18
Against this background it now seems necessary
to perform a controlled randomized double-blind
trial in SE to compare the efficacy and tolerability of
intravenous VPA with phenytoin or fosphenytoin.
Several open questions, such as loading and main-
tenance dosis, target groups and time point of
application in a new decision algorithmus for SE
have to be addressed in the future.
In conclusion, the intravenous application of VPA
seems to be a highly efficient and safe treatment in
many seizure emergency situations including SE. Our
data strongly support that theprofileofVPA includesa
fast action beside the well known slow-acting
mechanisms.19 It can have an effect even in cases
when other first-line AEDs have failed, but shows a
significantlybettertolerability, iseasiertohandleand
can be switched directly to a long-term antiepileptic
therapyoffirstchoice.Furthercontrolledcomparison
studies have to be performed in the future.Acknowledgement
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